...

Kazakhstan boosts pharma industry output as COVID-19 battle rages on

Business Materials 13 January 2021 16:48 (UTC +04:00)
Kazakhstan boosts pharma industry output as COVID-19 battle rages on

BAKU, Azerbaijan, Jan. 13

BY Nargiz Sadikhova – Trend:

Output in Kazakhstan’s pharmaceuticals industry has increased by 47 percent in 2020 as compared to 2019, Trend reports citing Kazakhstan’s Ministry of Industry and Infrastructural Development.

The ministry said the increase was due to an increase in the volume of products manufactured at local enterprises. For example, the volume of products manufactured by Khimfarm JSC has doubled. In addition, the company has increased its export volume by 2.5 times over the past 2 years.

Currently, the company-produced drugs are in wide demand in the countries of Central Asia and the EAEU. The products are exported to countries such as Kyrgyzstan, Tajikistan, Turkmenistan, Mongolia and Russia.

This year, the company plans to double exports by entering the Uzbek market, and one of the most important challenges is entering the drug market of the European Union. Thus, by 2023, the company looks to increase the volume of exports to 16 billion tenge ($38 million).

The Dolce-Pharm pharmaceutical company also increased the production volume by five times. The company’s industrial complex is located in the Almaty region, where 450 people are employed. The plant has six production workshops.

Abdi Ibrahim Global Pharm LLP has also increased the volume of its products by 3 percent in 2020 compared to 2019. At the moment, the main goals of the company are the further development of the pharmaceutical industry in Kazakhstan, and obtaining a leading position in the export of medicines among the CIS countries.

At the same time, the growth was ensured with an increase in the supply of medicines within the guaranteed volume of free medical care through the SK-Pharmacy Single Distributor, as well as with an increase in retail sales due to high demand among the population for medicines and medical products due to coronavirus pandemic.

The ministry also noted that the Comprehensive Plan for the Development of the Pharmaceutical Industry for 2020-2025 was approved in October 2020 and consists of 54 events and 8 sections.

---

Follow the author on Twitter: @nargiz_sadikh

Tags:
Latest

Latest